# Topotecan Using Convection-Enhanced Delivery (CED) in High Grade Glioma

> **NCT02278510** · EARLY_PHASE1 · COMPLETED · sponsor: **Michael Vogelbaum, MD, PhD** · enrollment: 3 (actual)

## Conditions studied

- Malignant Glioma
- WHO Grade III or IV Recurrent Glioma

## Interventions

- **DRUG:** Topotecan
- **DRUG:** Gadolinium DTPA
- **DEVICE:** Cleveland Multiport Catheter

## Key facts

- **NCT ID:** NCT02278510
- **Lead sponsor:** Michael Vogelbaum, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-09
- **Primary completion:** 2015-11-10
- **Final completion:** 2015-11-10
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2017-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02278510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02278510, "Topotecan Using Convection-Enhanced Delivery (CED) in High Grade Glioma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02278510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*